University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes
Welcome,         Profile    Billing    Logout  
 10 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tansey, Michael
NCT06173531: Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Recruiting
3
170
Europe, Canada, US
Carbetocin, ACP-101, Placebo
ACADIA Pharmaceuticals Inc.
Hyperphagia in Prader-Willi Syndrome
05/26
06/26
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
OraGrowtH210, NCT04614337 / 2020-000874-92: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency ( Trial)

Completed
2
82
Europe, US, RoW
LUM-201, rhGH Norditropin® pen (34 µg/kg)
Lumos Pharma, Lumos Pharma
Growth Hormone Deficiency
09/24
09/24
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
T1DES, NCT02734277: Type 1 Diabetes Extension Study

Recruiting
N/A
111
US
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Type 1 Diabetes Mellitus, T1DM, T1D
03/25
03/25
Baidal, David A
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
TN28, NCT04291703: STOP-T1D Low-Dose (ATG)

Active, not recruiting
2
101
US, RoW
Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
12/28
12/29
POSEIDON, NCT03406897: Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

Completed
1/2
25
US
Cholecalciferol, Vitamin D, Omega 3 fatty acid, Omega 3
Rodolfo Alejandro, Diabetes Research Institute Foundation
Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
07/24
07/24
DIPIT, NCT02586831: Diabetes Islet Preservation Immune Treatment

Withdrawn
1/2
45
US
Anti-Thymocyte Globulin (ATG), Thymoglobulin, Interleukin 2, Aldesleukin; IL-2 or Proleukin®, Exenatide, Bydureon®, Adalimumab, HUMIRA®, ATG Placebo, IL-2 Placebo, Adalimumab Placebo, Exenatide Placebo
Camillo Ricordi and Jay Skyler, Diabetes Research Institute Foundation
Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
12/28
12/29
NCT02846571: Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

Recruiting
1/2
2
US
Human Pancreatic Islet Transplantation
Midhat H. Abdulreda, Diabetes Research Institute Foundation, Bascom Palmer Eye Institute
Diabetes
12/26
12/27
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27
NCT01999361: Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Recruiting
N/A
18
US
Myfortic, mycophenolic acid
Rodolfo Alejandro
Type 1 Diabetes Mellitus
01/27
12/28
NCT01999374: Long Term Follow up of Recipients of Functional Islet Allografts

Recruiting
N/A
30
US
Rodolfo Alejandro
Type 1 Diabetes Mellitus
03/27
12/28
NCT02000687: Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss

Recruiting
N/A
60
US
Rodolfo Alejandro
Type 1 Diabetes Mellitus
12/27
07/28
Hemann, Holly
DESIGNATE, NCT05574335: Siplizumab in T1DM

Active, not recruiting
1/2
120
US
Siplizumab, TCD 601
National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
12/26
12/27

Download Options